Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

Inclusion Criteria: * Type 2 Diabetes mellitus patients who are treated with metformin monotherapy 1,000 mg daily for at least 3 months * The patient is required to have HbA1c 6.5-11.0% * BMI in the range of 22-48 kg/m2 Exclusion Criteria: * Severe or uncontrolled Type 2 diabetes mellitus (HbA1c\> 11.0%) * Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months * Congestive heart failure requiring pharmacologic treatment * Any of following within past 6 months: (1) myocardial infarction; (2) unstable angina (3) coronary artery bypass surgery or percutaneous coronary intervention * Liver disease such as cirrhosis or chronic active hepatitis